Skip to main content
Top
Published in: Medical Microbiology and Immunology 1/2009

01-02-2009 | Original Investigation

Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells

Authors: Kai-Fu Tang, Min Chen, Jing Xie, Guan-Bin Song, Yi-Song Shi, Qi Liu, Zhe-Chuan Mei, Alexander Steinle, Hong Ren

Published in: Medical Microbiology and Immunology | Issue 1/2009

Login to get access

Abstract

Hepatitis B virus (HBV) replicates in most tumor tissues of patients with HBV-associated hepatocellular carcinoma (HCC). In the present study, we have shown that the expression of HBV in the HCC cell lines, HepG2 and Huh7, down-regulated the expression of MHC class I-related molecule A (MICA), a ligand of the NKG2D receptor. Inhibition of HBV expression by small interference RNAs (siRNAs) in HepG2.2.15, a cell line that constitutively expresses HBV, induced up-regulation of MICA. The up-regulation of MICA increased the lysis of HepG2.2.15 cells by NK cells. Our results suggest that HBV compromises the innate immune system in HCC patients and that inhibition of HBV replication by siRNAs may enhance the antitumor immune response.
Literature
2.
go back to reference El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823PubMed El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823PubMed
6.
go back to reference van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG et al (2004) Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40:738–746. doi:10.1002/hep.20366 PubMedCrossRef van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG et al (2004) Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40:738–746. doi:10.​1002/​hep.​20366 PubMedCrossRef
7.
go back to reference Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C et al (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963–971. doi:10.1053/jhep.2001.23045 PubMedCrossRef Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C et al (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963–971. doi:10.​1053/​jhep.​2001.​23045 PubMedCrossRef
8.
go back to reference Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S et al (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968–975. doi:10.1172/JCI3731 PubMedCrossRef Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S et al (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968–975. doi:10.​1172/​JCI3731 PubMedCrossRef
9.
go back to reference Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS et al (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41:722–730. doi:10.1002/hep.20644 PubMedCrossRef Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS et al (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41:722–730. doi:10.​1002/​hep.​20644 PubMedCrossRef
12.
go back to reference Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T et al (2003) Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 104:354–361. doi:10.1002/ijc.10966 PubMedCrossRef Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T et al (2003) Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 104:354–361. doi:10.​1002/​ijc.​10966 PubMedCrossRef
14.
go back to reference Chen Y, Cheng M, Tian Z (2006) Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell Mol Immunol 3:373–378PubMed Chen Y, Cheng M, Tian Z (2006) Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell Mol Immunol 3:373–378PubMed
16.
go back to reference Catterall AP, Murray-Lyon IM, Zuckerman AJ, Harrison TJ (1994) Southern hybridisation analysis of HBV DNA in peripheral blood leucocytes and of different cell types: changes during the natural history and with interferon-alpha therapy in patients with hepatitis B virus infection. J Med Virol 43:269–275. doi:10.1002/jmv.1890430314 PubMedCrossRef Catterall AP, Murray-Lyon IM, Zuckerman AJ, Harrison TJ (1994) Southern hybridisation analysis of HBV DNA in peripheral blood leucocytes and of different cell types: changes during the natural history and with interferon-alpha therapy in patients with hepatitis B virus infection. J Med Virol 43:269–275. doi:10.​1002/​jmv.​1890430314 PubMedCrossRef
17.
19.
20.
go back to reference Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2:255–260. doi:10.1038/85321 PubMedCrossRef Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2:255–260. doi:10.​1038/​85321 PubMedCrossRef
21.
go back to reference Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M et al (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65:6321–6329. doi:10.1158/0008-5472.CAN-04-4252 PubMedCrossRef Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M et al (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65:6321–6329. doi:10.​1158/​0008-5472.​CAN-04-4252 PubMedCrossRef
23.
go back to reference McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H et al (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21:639–644. doi:10.1038/nbt824 PubMedCrossRef McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H et al (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21:639–644. doi:10.​1038/​nbt824 PubMedCrossRef
24.
go back to reference Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002–1007. doi:10.1038/nbt1122 PubMedCrossRef Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002–1007. doi:10.​1038/​nbt1122 PubMedCrossRef
Metadata
Title
Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells
Authors
Kai-Fu Tang
Min Chen
Jing Xie
Guan-Bin Song
Yi-Song Shi
Qi Liu
Zhe-Chuan Mei
Alexander Steinle
Hong Ren
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Medical Microbiology and Immunology / Issue 1/2009
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-008-0101-6

Other articles of this Issue 1/2009

Medical Microbiology and Immunology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.